Oscar Health (NYSE:OSCR) Shares Down 8.8% on Analyst Downgrade

Posted by Stanley Muller on Nov 6th, 2026

Oscar Health, Inc. (NYSE:OSCR – Get Free Report) shares dropped 8.8% during trading on Friday after Piper Sandler lowered their price target on the stock from $48.00 to $45.00. Piper Sandler currently has an overweight rating on the stock. Oscar Health traded as low as $30.39 and last traded at $30.2510. 3,713,784 shares traded hands during mid-day trading, a decline of 45% from the average daily volume of 6,726,105 shares. The stock had previously closed at $33.18.

Other equities research analysts also recently issued reports about the company. Wells Fargo & Company lifted their price objective on Oscar Health from $20.00 to $27.00 and gave the stock an “equal weight” rating in a report on Thursday, August 13th. Weiss Ratings raised shares of Oscar Health from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. Raymond James Financial raised their price target on shares of Oscar Health from $34.00 to $42.00 and gave the stock an “outperform” rating in a research report on Friday, September 18th. Stephens restated an “equal weight” rating and issued a $34.00 price target on shares of Oscar Health in a research note on Thursday, September 17th. Finally, Robert W. Baird upped their price target on shares of Oscar Health from $27.00 to $33.00 and gave the company a “neutral” rating in a report on Thursday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $34.60.

Check Out Our Latest Analysis on OSCR

Insider Buying and Selling at Oscar Health

In related news, CFO Richard Blackley sold 28,869 shares of the business’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $31.45, for a total value of $907,930.05. Following the completion of the sale, the chief financial officer directly owned 1,046,108 shares of the company’s stock, valued at $32,900,096.60. The trade was a 2.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam Mcananey sold 9,092 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $31.45, for a total value of $285,943.40. Following the sale, the insider owned 209,004 shares in the company, valued at $6,573,175.80. The trade was a 4.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 874,451 shares of company stock valued at $26,761,671. Corporate insiders own 22.64% of the company’s stock.

Key Stories Impacting Oscar Health

Here are the key news stories impacting Oscar Health this week:

Positive Sentiment: Oscar reported Q3 adjusted earnings of $0.49 per share, versus analysts’ expected loss, and revenue of $5.14 billion against a $4.69 billion estimate. Revenue grew 72.1% year over year. Oscar Health beats Q3 estimates
Positive Sentiment: Operating performance improved: the company swung to a $167.3 million profit, membership increased 27.2% to 2.69 million, and its medical loss ratio fell to 84%. The earnings call also highlighted improved medical costs and operating efficiencies. Q3 revenue, membership and margins
Positive Sentiment: Oscar raised its 2026 outlook again, projecting revenue of $19 billion to $19.3 billion, above FactSet’s $18.64 billion estimate. Management also pointed to expansion as a source of potential 2027 growth. Oscar raises 2026 revenue outlook
Positive Sentiment: Zacks added OSCR to its Rank #1 (Strong Buy) growth-stock list, providing another favorable analyst signal. Zacks growth-stock list
Negative Sentiment: Piper Sandler cut its price target to $45 from $48, although it maintained an Overweight rating. The reduced target may temper enthusiasm despite its stated upside from the referenced share price. Piper Sandler analyst recommendations
Negative Sentiment: Shares slipped after the results even as some healthcare peers rose, suggesting the strong quarter and outlook may not have been enough to sustain immediate buying interest. Oscar slips as peers climb

Institutional Investors Weigh In On Oscar Health

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE increased its stake in Oscar Health by 205.1% during the first quarter. Bank of America Corp DE now owns 2,860,310 shares of the company’s stock valued at $32,808,000 after purchasing an additional 1,922,732 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in Oscar Health by 107.5% during the third quarter. Assenagon Asset Management S.A. now owns 2,589,708 shares of the company’s stock worth $79,867,000 after acquiring an additional 1,341,716 shares during the period. Wedge Capital Management L L P NC bought a new stake in shares of Oscar Health in the 2nd quarter worth approximately $32,855,000. Dimensional Fund Advisors LP lifted its stake in Oscar Health by 22.1% in the first quarter. Dimensional Fund Advisors LP now owns 4,192,777 shares of the company’s stock valued at $48,078,000 after buying an additional 759,837 shares during the last quarter. Finally, Halter Ferguson Financial Inc. boosted its stake in Oscar Health by 93.3% during the 3rd quarter. Halter Ferguson Financial Inc. now owns 1,211,825 shares of the company’s stock valued at $37,373,000 after purchasing an additional 584,818 shares during the period. 75.70% of the stock is owned by institutional investors and hedge funds.

Oscar Health Stock Performance

The company has a debt-to-equity ratio of 0.21, a current ratio of 1.09 and a quick ratio of 1.09. The stock has a fifty day moving average price of $31.80 and a two-hundred day moving average price of $23.89. The company has a market cap of $9.34 billion, a P/E ratio of 21.64, a PEG ratio of 0.39 and a beta of 2.56.

Oscar Health (NYSE:OSCR – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.63. Oscar Health had a return on equity of 38.45% and a net margin of 3.60%. The business had revenue of $5.14 billion during the quarter, compared to analyst estimates of $4.69 billion. During the same period in the prior year, the company posted ($0.53) EPS. The business’s revenue for the quarter was up 72.1% compared to the same quarter last year. On average, equities analysts forecast that Oscar Health, Inc. will post 1.83 earnings per share for the current fiscal year.

Oscar Health Company Profile

(Get Free Report)

Oscar Health, Inc is a technology-focused health insurance company that provides health plans and related services in the United States. The company primarily serves individuals and families purchasing coverage through the Affordable Care Act’s health insurance marketplace, as well as small businesses and their employees.

Oscar combines health insurance products with digital tools designed to help members manage their care. Its services include online enrollment, virtual care, provider search and appointment support, care navigation, claims and benefits information, and member engagement through web and mobile applications.